crypto to cash exchange, Knowledge

The Bank of Japan believes that the cost of waiting for the next rate hike is not high, but it is also open to raising interest rates this month. According to informed sources, Bank of Japan officials believe that there is almost no cost to wait before raising interest rates, and they are still open to raising interest rates next week, depending on data and market development. According to people familiar with the matter, even if the Bank of Japan decides to wait until January next year or a little longer before raising interest rates, the relevant authorities believe that this will not bring huge costs, because there are signs that there is little risk of inflation overshoot. According to people familiar with the matter, officials think it is only a matter of time before the next rate hike, because the economy and inflation are in line with their forecasts. According to people familiar with the matter, officials will make a final decision only after carefully evaluating the data and financial markets before announcing the policy decision in December. Bank of Japan Governor Kazuo Ueda and his committee will discuss next week whether it is necessary to raise the benchmark interest rate from 0.25%. Unlike the situation in July, the yen did not show a strong weakness, so the Bank of Japan believes that the risk of the yen pushing up inflation has weakened.The Shanghai Stock Exchange approved the refinancing of Dizhe Medicine to support the development of new quality productivity. The announcement of Dizhe Medicine shows that the private placement plan of Dizhe Medicine in science and technology innovation board has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of unprofitable enterprises in Shanghai Stock Exchange has been approved since the issuance of the Eight Measures on Deepening science and technology innovation board's Reform, Service, Scientific and Technological Innovation and Development of New Productivity by CSRC. As a listed company with the fifth standard in science and technology innovation board, Dizhe Medicine's refinancing has been approved by Shanghai Stock Exchange, which reflects the institutional inclusiveness and support of the capital market for supporting new quality productivity and unprofitable technology-based enterprises with key core technologies, great market potential and outstanding scientific and technological attributes. Dizhe Medicine said that the company's refinancing will help the company to further accelerate product research and development and production base construction, create new quality productivity, implement major national strategies, promote products to the sea, and give scientific and technological impetus to the development of biomedical economy. (Sina Technology)Xia Yiping issued an internal letter: the company will merge duplicate departments and cut unprofitable projects. Xia Yiping, CEO of Extreme Vietnam, communicated with all employees through video conference, frankly indicating that the company is currently experiencing difficulties, and the company needs to adjust immediately and enter the 2.0 stage of entrepreneurship. The management will go all out to tide over the difficulties with all employees. In the letter sent on the same day, Xia Yiping said that Jiyue Automobile will do well in four aspects when it enters the stage of entrepreneurship 2.0: insisting on long-term investment in core technologies to maintain its leading edge; Strengthen sales and service capacity building to cope with fierce market competition; Merge departments and posts with duplicate functions, change inefficient internal workflow, and cut projects that cannot improve financial performance in the short term. (Auto has a style)

Southbound funds bought a net of 7.285 billion yuan today, and southbound funds bought a net of 7.285 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), TraHK and China Mobile received net purchases of HK$ 2.719 billion and HK$ 352 million respectively; Tencent Holdings ranked first in net sales, amounting to HK$ 491 million; In terms of Hong Kong Stock Connect (Shenzhen Stock Connect), TraHK and Hang Seng China Enterprises received net purchases of HK$ 2.501 billion and HK$ 665 million respectively; Meituan -W ranked first in net sales, amounting to HK$ 602 million.Albertson terminated its merger with krogh and announced an increase in dividend and repurchase plan. albertson Company announced that it had exercised its right to terminate its merger agreement with krogh, because the US District Court in Oregon and the District Court in Washington issued an injunction on the proposed merger on December 10th. Vivek Sankaran, CEO of the company, commented: "In view of the recent decision of the federal and state courts to block the proposed merger between the company and krogh, we have made a difficult decision to terminate the merger agreement. We are very disappointed with the court's decision. " In addition, the board of directors of albertson Company plans to increase the quarterly cash dividend from $0.12 to $0.15 per share, and approved a stock repurchase plan of up to $2 billion.Health Yuan: Obtained the commitment letter of stock repurchase loan from financial institutions of no more than 238 million yuan. Health Yuan announcement, the company recently obtained the commitment letter of loan from Industrial Bank, with a loan amount of no more than 238 million yuan, no more than 90% of the upper limit of repurchase amount, and a loan period of no more than 36 months, which is specially used to repurchase shares of listed companies. The total amount of the company's actual loan and the amount of the repurchased funds shall not exceed the upper limit of the amount of this repurchase program. The commitment letter of the financial institution's stock repurchase loan obtained this time does not represent the company's commitment to the repurchase amount. The specific number of shares repurchased shall be subject to the actual number of shares repurchased at the expiration of the repurchase period.

Beijing Auto: BAIC Investment and Hyundai Motor invested US$ 1.095 billion in Beijing Hyundai. Beijing Auto announced that on December 11, 2024, BAIC Investment and Hyundai Motor entered into an agreement, and both parties agreed to jointly invest US$ 1.095 billion in Beijing Hyundai according to the proportion of their respective registered capital, and both parties invested US$ 548 million respectively. The capital injection will be carried out in stages. After the capital injection is completed, the registered capital of Beijing Hyundai will increase to US$ 4.074 billion, and Beijing Hyundai will still be owned by BAIC Investment and Hyundai Motor respectively, and will continue to be accounted for as a joint venture of the Company.The Shanghai Stock Exchange approved the refinancing of Dizhe Medicine to support the development of new quality productivity. The announcement of Dizhe Medicine shows that the private placement plan of Dizhe Medicine in science and technology innovation board has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of unprofitable enterprises in Shanghai Stock Exchange has been approved since the issuance of the Eight Measures on Deepening science and technology innovation board's Reform, Service, Scientific and Technological Innovation and Development of New Productivity by CSRC. As a listed company with the fifth standard in science and technology innovation board, Dizhe Medicine's refinancing has been approved by Shanghai Stock Exchange, which reflects the institutional inclusiveness and support of the capital market for supporting new quality productivity and unprofitable technology-based enterprises with key core technologies, great market potential and outstanding scientific and technological attributes. Dizhe Medicine said that the company's refinancing will help the company to further accelerate product research and development and production base construction, create new quality productivity, implement major national strategies, promote products to the sea, and give scientific and technological impetus to the development of biomedical economy. (Sina Technology)Pinduoduo stocks fell more than 3% before trading.